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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2015, FormosaBackground/Purpose: Inflammation plays an important role in promoting ovarian tumorigenesis
and cancer progression. However, the relationship between polymorphisms in inflammatory
responsegenesand risk ofovariancancer remainspoorlyunderstood. In this study,we investigated
the association of PPARG Pro12Ala, IL6-174G/C, E-selectin S128R, NFKB1-94 ins/del, NFKBIA-
826C/T, and ICAM-1 K469E polymorphisms with ovarian cancer risk in a Chinese population.
Methods: Genotyping of the polymorphisms was performed on 687 cases and 687 controls em-
ploying the PCR-RFLP technique, and the logistic regression model was used to measure the risk
association.
Results: A significantly increased risk association was observed for the heterozygous genotypes
of PPARG [odds ratio (OR) Z 1.52, 95% confidence interval (CI) Z 1.01e2.29] and E-selectin
(OR Z 1.77, 95% CI Z 1.07e2.93) polymorphisms, as well as the homozygous ins/ins genotype
of NFKB1 polymorphism (ORZ 1.39, 95% CIZ 1.00e1.92). By contrast, ICAM-1 KE genotype was
associated with a decreased ovarian cancer risk (ORZ 0.77, 95% CIZ 0.60e0.98). In addition,
the NFKB1 del/del þ NFKBIA TT combination was also found to be associated with a decreased
ovarian cancer risk, with OR Z 0.12 (95% CI Z 0.01e0.95). The associations of the NFKB1 and
ICAM-1 polymorphisms replicated the findings of previous reports, assuring the reliability of the
results obtained.
Conclusion: NFKB1 and ICAM-1 polymorphisms could serve as useful ovarian cancer risk predic-
tion biomarkers for the Chinese population, while the utility of PPARG and E-selectin polymor-
phisms as biomarkers requires further confirmation in independent ovarian cancer cohorts.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights
reserved.ave no conflicts of interest relevant to this article.
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32 Z.-H. Lu et al.IntroductionOvarian cancer is one of the leading forms of cancer, both
in China and worldwide.1 Each year, there is an estimated
225,500 new incidences of ovarian cancer cases globally.2
The lack of effective screening methods causes >70% of
ovarian cancer patients to be diagnosed at late stages,
which leads to the low 5-year survival rate and high mor-
tality rate of the disease. Worldwide, ovarian cancer con-
tributes to 114,000 deaths annually.3 A method for the
identification of individuals at a higher risk of the cancer is
therefore necessary for improving ovarian cancer screening
strategy.
The principal risk factors for the occurrence of ovarian
cancer are germ line mutations in the BRCA1 or BRCA2
genes.4 However, the carriers of such mutations account for
only a small portion of total ovarian cancer cases, and a
substantial proportion of ovarian cancer risk among spo-
radic cases remained unexplained. It has been suggested
that common low penetrance genetic variations could
confer moderate risk to ovarian cancer cases without a
heritable basis.5 Single nucleotide polymorphisms of genes
involved in cancer-related pathways represent the candi-
dates of such genetic variations.
Inflammation has been established as an underlying
cause in the development of many cancers.6 Several events
which delay inflammation in the ovaries, such as childbirth
and oral contraceptive use, have been associated with a
reduced risk of ovarian cancer.7 On the contrary, events
which cause inflammation, such as endometriosis, have
been suggested to increase the risk of ovarian cancer.8 It
has been thought that inflammation could induce and
activate several oxidant-generating enzymes, which can
lead to damages in the DNA. Given the important link be-
tween inflammation and ovarian carcinogenesis, inherited
variation in inflammatory response genes could affect
ovarian cancer susceptibility.
Polymorphisms in several inflammatory response genes,
such as PPARG Pro12Ala polymorphism, IL6 -174G/C poly-
morphism, E-selectin S128R (A561C) polymorphism, NFKB1-
94 ins/del polymorphism, NFKBIA -826C/T polymorphism,
and ICAM-1 K469E polymorphism, have been found to be
associated with various cancers.9e16 However, the
involvement of these polymorphisms in ovarian cancer in
the Chinese population has not been well established. To
address this matter, we investigated the association be-
tween the six inflammatory response genetic poly-
morphisms mentioned above and the risk of ovarian cancer
in a Chinese population.
Materials and methods
Study participants
The study was approved by the Medical Research Ethics
Board of the First Affiliated Hospital of Nanchang Univer-
sity, Nanchang City, China and all samples were collected
from the above hospital from July 2010 to December 2013.
A total of 687 females who were histopathologically
confirmed ovarian cancer patients and 687 controls wererecruited into the study. Controls were disease-free in-
dividuals without cancers and age-matched to the cases in
terms of frequency. Blood samples were collected from the
participants after obtaining written informed consent.
Genotyping
Genomic DNA was extracted from the blood samples ob-
tained using EasyPure Blood Genomic DNA Kit (TransGen
Biotech, Beijing, China) according to the manufacturer’s
protocol. The genomic DNA obtained was then used in po-
lymerase chain reaction (PCR). The genetic polymorphisms
were detected by the PCR-restriction fragment length
polymorphism (RFLP) method. Researchers were blinded to
the identity and the caseecontrol status of the samples.
For all polymorphisms,w10% of the samples were chosen at
random and sequenced to confirm the genotypes.
PPARG Pro12Ala polymorphism
The PCR primers of PPARG Pro12Ala polymorphism used
were 50-GCC AAT TCA AGC CCA GTC-30 and 50-GAT ATG TTT
GCA GAC AGT GTA TCA GTG AAG GAA TCG CTT TCC-30. The
PCR condition was 5 minutes of initial denaturation at 94C,
followed by 35 cycles of 1 minute at 94C, 30 seconds at
60C, 30 seconds at 72C, and a final extension for 5 mi-
nutes at 72C. The PCR amplification produced fragment of
270 bp in size. BstUI restriction enzyme was then used to
digest the 270 bp fragment for determination of genotype.
The CC genotype remained uncut after restriction diges-
tion. The GG genotype gave a 227 bp and a 43 bp fragment,
and heterozygous genotype (GC) genotype was detected by
the presence of all the above bands in agarose gel.
IL6-174G/C polymorphism
The PCR condition used for IL6 -174G/C polymorphism was 5
minutes of initial denaturation at 94C, followed by 35 cy-
cles of 45 seconds at 94C, 30 seconds at 58C, 30 seconds
at 72C, and a final extension for 5 minutes at 72C. The
primers used were 50-TGA CTT CAG CTT TAC TCT TGT-30 and
50-CTG ATT GGA AAC CTT ATT AAG-30. The PCR reaction
gave an amplification product of 161 bp in size. The frag-
ment was then digested by Hsp 92II restriction enzyme. The
GG genotype remained 161 bp on agarose gel as it was
uncut by the restriction enzyme. However, the restriction
digestion produced two smaller fragments, which were
118 bp and 43 bp in size, for CC genotype. In addition,
heterozygous genotype (GC) was found to have all the
fragments detected in homozygous genotypes, which were
fragments with sizes of 161 bp, 118 bp, and 43 bp.
E-selectin S128R (A561C) polymorphism
The E-selectin S128R (A561C) polymorphismwas genotypedby
first amplifying the region of interest under the following
conditions: 10 minutes of initial denaturation at 94C, fol-
lowedby35 cycles of 30 seconds at 94C,30 secondsat 60.5C,
30 seconds at 72C, and a final extension for 10 minutes at
72C. The PCR primers used were 50-ATGGCACTCTGTAG-
GACTGCT-30 and 50-GTCTCAGCTCACGATCACCAT-30. The
Table 1 Characteristics of cases and controls.
Characteristic Case
(n Z 687)
Control
(n Z 687)
p
Age (y)
Mean  SD 60.0  8.78 59.5  8.75 0.33
Median 64 60
Smoking habit
Never smoker 433 451 0.31
Ever smoker 254 236
Oral contraceptive
Never user 505 493 0.47
Ever user 182 194
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striction enzyme. The AA genotype was cleaved into
219 þ 138 bp fragments, whereas the CC genotype was not
cleaved (357 bp). Heterozygotes (AC) showed all the above
bands on agarose gel.
NFKB1-94 ins/del polymorphism
The PCR condition used for NFKB1-94 ins/del polymorphism
was 5 minutes of initial denaturation at 94C, followed by
35 cycles of 30 seconds at 94C, 30 seconds at 58C, 50
seconds at 72C, and a final extension for 7 minutes at 72C.
The primers used were 50-TGG GCA CAA GTC GTT TAT GA-30
and 50-CTG GAG CCG GTA GGG AAG-03. PflMI restriction
enzyme was used to restrict the PCR product. For ins/ins
genotype, a 281 bp fragment was observed on agarose gel
upon digestion, as no restriction site was found in the
fragment. A 240 bp and a 45 bp fragment were seen for the
del/del genotype, while a 281 bp, a 240 bp, and a 45 bp
fragment were found in the Ins/del genotype after re-
striction enzyme digestion.
NFKBIA-826C/T polymorphism
The NFKBIA -826C/T polymorphism was genotyped by first
amplifying the region of interest by using the following PCR
primers: 50-GGT CCT TAA GGT CCA ATC G-30 and 50-GTT GTG
GAT ACC TTG CAC TA-30. The PCR was performed with 10
minutes of initial denaturation at 94C, followed by 35 cy-
cles of 1 minute at 94C, 30 seconds at 59.5C, 45 seconds
at 72C, and a final extension for 5 minutes at 72C.This
produced an amplicon of 200 bp in size. Restriction enzyme
digestion was performed with BfaI. The TT genotype was
uncut by the enzyme and remained 200 bp, but the TT
genotype was cleaved into 180 þ 20 bp bands. Heterozy-
gotes showed all three bands on agarose gel.
ICAM-1 K469Epolymorphism
The region containing the ICAM-1 K469E polymorphism was
amplified by using 50-GGA ACC CAT TGC CCG AGC-30 forward
primer and 50-GGT GAG GAT TGC ATT AGG TC-30 reverse
primer, which produced a product of 223 bp. The PCR
condition comprised of 5 minutes of initial denaturation at
94C, followed by 35 cycles of 45 seconds at 94C, 30 sec-
onds at 59C, 45 seconds at 72C, and a final extension for 5
minutes at 72C. BstUI restriction enzyme was then used to
cleave the fragment. The AA genotype did not contain the
restriction site of the enzyme, and remained 223 bp on
agarose gel after the reaction. However, the GG genotype
was cleaved into 136 þ 87 bp bands, and heterozygotes
(AG) contained all the bands (223 þ 136 þ 87 bp).
Statistical analysis
SPSS Statistics (version 19; SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. The difference between cases
and controls in terms of demographic characteristics and
genotype distribution were calculated by using c2 or Stu-
dent t test, whenever appropriate. Binary logistic regres-
sion models were used to calculate the odds ratios (ORs)and their 95% confidence intervals (CIs) for measuring of
the association of the polymorphisms and ovarian cancer
risk, with the wild type genotype served as the reference.
All statistical analyses were performed with p < 0.05.Results
Characteristics of cases and controls
The demographic characteristics of the cases and controls
are shown in Table 1. The mean and median ages of the
cases were 60.0  8.78 years and 64 years respectively,
whereas those of the controls were 59.5  8.75 years and
60 years. No significant difference was observed between
cases and controls in terms of age (pZ 0.33). Four hundred
and thirty three of the cases were never smokers and 254
were ever smokers. However, 451 controls and 236 controls
were never smokers and ever smokers, respectively. The
difference in the number of never and ever smokers be-
tween cases and controls was also not statistically signifi-
cant (p Z 0.31). In terms of oral contraceptive use, 505
cases were never users and 182 were ever users, in contrast
to 493 never users and 194 ever users in controls. Similarly,
the difference in oral contraceptive use between cases and
controls was not statistically significant (p Z 0.47).
Genotypic distribution of the polymorphisms
The genotypic distribution of the polymorphisms is shown in
Table 2. For the PPARG polymorphism, 624 cases, 62 cases,
and one cases had Pro/Pro, Pro/Ala, and Ala/Ala genotypes
respectively, in comparison to 643 controls, 42 controls,
and two controls. No significant difference was observed
between cases and controls in the distribution of Pro/Pro
(pZ 0.06) and Ala/Ala (pZ 0.57) genotypes. However, the
Pro/Ala genotype appeared to be significantly different
between cases and controls (p Z 0.04), with a higher fre-
quency in the cases.
For the IL6 polymorphism, 684 cases and 676 controls
had GG genotype. However, four cases and 11 controls had
GC genotype. The difference between cases and controls in
these genotypes were not statistically significant
(p Z 0.08). None of the participants studied had the CC
genotype.
Table 2 Genotypic distribution of the six polymorphisms.
Genotype Case
(n Z 687)
Controls,
(n Z 687)
p
PPARG
Pro/Pro 624 643 0.06
Pro/Ala 62 42 0.04
Ala/Ala 1 2 0.57
IL6
GG 683 676 0.08
GC 4 11 0.08
CC 0 0 1.00
E-selectin
AA 662 644 0.03
AC 25 43 0.03
CC 0 0 1.00
NFKB1
Del/Del 221 253 0.07
Del/Ins 351 339 0.51
Ins/Ins 115 95 0.13
NFKBIA
CC 486 478 0.64
CT 181 190 0.58
TT 20 19 0.87
ICAM-1
KK 209 180 0.08
KE 322 362 0.03
EE 156 145 0.47
Significant p values are shown in bold.
Table 3 Risk association of the polymorphisms with
ovarian cancer.
Genotype Case
(n Z 687)
Controls
(n Z 687)
OR (95% CI) p
PPARG
Pro/Pro 624 643 Reference d
Pro/Ala 62 42 1.52 (1.01e2.29) 0.04
Ala/Ala 1 2 0.52 (0.05e5.70) 0.59
IL6
GG 683 676 Reference d
GC 4 11 0.36 (0.11e1.14) 0.08
CC 0 0 d d
E-selectin
AA 662 644 Reference d
AC 25 43 1.77 (1.07e2.93) 0.03
CC 0 0 d d
NFKB1
Del/Del 221 253 Reference d
Del/Ins 351 339 1.19 (0.94e1.50) 0.15
Ins/Ins 115 95 1.39 (1.00e1.92) 0.05
NFKBIA
CC 486 478 Reference d
CT 181 190 0.94 (0.74e1.19) 0.59
TT 20 19 1.04 (0.55e1.96) 0.92
ICAM-1
KK 209 180 Reference d
KE 322 362 0.77 (0.60e0.98) 0.04
EE 156 145 0.93 (0.69e1.25) 0.62
Significant p values are shown in bold.
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pants studied had the variant genotype (CC) for E-selectin
S128R (A561C) polymorphism. Six hundred and sixty two
cases had AA genotype, and only 25 had AC genotype.
However, 644 controls and 43 controls had AA and AC ge-
notypes, respectively. The difference between cases and
controls in the genotypic distribution of AA and AC geno-
types was statistically significant, with p Z 0.03. The AA
genotype was overrepresented in the cases, and the AC
genotype was overrepresented in the control group.
Meanwhile, for NFKB1 polymorphism, 221 cases and 253
controls had del/del genotype. However, 351 cases and 339
controls had the heterozygous del/ins genotype, and 115
cases and 95 controls had the ins/ins genotype. Statistically
significant difference between cases and controls was not
observed for the polymorphism. The p values of the del/
del, del/ins and ins/ins genotypes were pZ 0.07, pZ 0.51,
and p Z 0.13, respectively.
Four hundred and eighty six cases had the CC genotype
for the NFKBIA polymorphism, while 181 cases and 20 cases
had CT and TT genotypes, respectively. By comparison, 478
controls, 190 controls, and 19 controls had the three
respective genotypes. The differences between cases and
controls in the distribution of the CC, CT, and TT genotypes
were not statistically significant, with p Z 0.64, p Z 0.58,
and p Z 0.87, respectively.
However, the frequencies of KK, KE, and EE genotypes for
the ICAM-1 polymorphism were in 209 cases, 322 cases, and
156 cases, and in 180 controls, 362 controls, and 145 controls.
Significant difference was not observed between cases and
controls in the frequency distribution of the KK (p Z 0.08)and EE (pZ 0.47) genotypes. However, a significant differ-
ence was observed for the heterozygote KE genotype
(pZ 0.03), which is overrepresented in the control group.
All the genotypic distribution followed HardyeWeinberg
equilibrium (p > 0.05).
Risk association of the polymorphisms
The association of the inflammatory gene polymorphisms
with ovarian cancer risk was measured in OR units, with the
wild type genotype served as the reference. The risk as-
sociation was summarized in Table 3. For the PPARG poly-
morphism, the Pro/Ala genotype was found to be
significantly associated with an increased ovarian cancer
risk (p Z 0.04), with OR Z 1.52, 95% CI Z 1.01e2.29. The
Ala/Ala genotype was not associated with the risk of
ovarian cancer significantly (p Z 0.59). Similarly, no sig-
nificant risk association was observed for the GC genotype
of the IL6 polymorphism (pZ 0.08). The risk association of
the CC genotype could not be measured because none of
the study participants carried the genotype. For the E-
selectin polymorphism, a significantly increased ovarian
cancer risk association was observed for the AC genotype
(p Z 0.03), with OR Z 1.77 (95% CI Z 1.07e2.93), and
similar to the IL6 polymorphism, the association of the
variant genotype could not be calculated. The NFKB1
polymorphism, however, was found to be associated with
ovarian cancer risk, with the ins/ins genotype increasing
the risk by 39% (OR Z 1.39, 95% CI Z 1.00e1.92), at
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icant association was observed for the heterozygous del/ins
genotype (p Z 0.15). For the NFKBIA polymorphism, none
of the genotypes was observed to be associated with the
risk of ovarian cancer (p Z 0.59 for CT genotype and
p Z 0.92 for TT genotype). Finally, for the ICAM-1 poly-
morphism, a significant decreased risk association was
observed for the KE genotype, with OR Z 0.77 (95%
CI Z 0.60e0.98; p Z 0.04). Despite this, significant asso-
ciation was not observed for the variant EE genotype
(p Z 0.62).
Combinations of NFKB1 and NFKBIA genotypes and
their association with ovarian cancer risk
Because NFKB1 and NFKBIA share the same signaling
pathway, we investigated the association of NFKB1 and
NFKBIA combination genotypes with the risk of ovarian
cancer. The association is shown in Table 4. The numbers of
cases who had the NFKB1 del/del þ NFKBIA CC, NFKB1 del/
ins þ NFKBIA CC, NFKB1 ins/ins þ NFKBIA CC, NFKB1 del/
del þ NFKBIA CT, NFKB1 del/ins þ NFKBIA CT, NFKB1 ins/
ins þ NFKBIA CT, NFKB1 del/del þ NFKBIA TT, NFKB1 del/
ins þ NFKBIA TT, and NFKB1 ins/ins þ NFKBIA TT genotypes
were 161, 246, 79, 59, 93, 29, 1, 12, and 7 respectively,
while those of the controls were 172, 241, 65, 72, 93, 25, 9,
5, and 5. Of these, significant difference between cases and
controls was observed only for the NFKB1 del/del þ NFKBIA
TT genotype. The NFKB1 del/del þ NFKBIA TT was over-
represented in controls, and the combination genotype was
therefore associated with a reduced ovarian cancer risk,
with OR Z 0.12 (95% CI Z 0.01 0.95), p Z 0.04.
Discussion
The link between inflammation and cancer development
has been well established.6 However, studies investigating
the relationship between inflammatory gene poly-
morphisms and cancer risk have generated contradictory
findings.9e16 The allelic distributions of various poly-
morphisms could vary geographically and ethnically, thus
leading to the discordant findings between these poly-
morphisms and cancer risk. In this study, we reported the
association between six inflammatory gene polymorphisms
and ovarian cancer risk in a Chinese population. Our anal-
ysis showed that three of the polymorphisms wereTable 4 Combinations of NFKB1 and NFKBIA polymorphism and
NFKB1 genotype NFKBIA genotype Case (n Z 687)
Del/del CC 161
Del/ins CC 246
Ins/ins CC 79
Del/del CT 59
Del/ins CT 93
Ins/ins CT 29
Del/del TT 1
Del/ins TT 12
Ins/ins TT 7
Significant p values are shown in bold.associated with an increased ovarian cancer risk, and one
polymorphism was associated with a decreased ovarian
cancer risk.
PPARG encodes for PPAR-g, a member of the nuclear
hormone receptor super family which has been shown to
play a pivotal role in regulating cell differentiation, cell
growth, glucose, and lipid metabolism, and several other
processes known to be important in carcinogenesis.17,18
Activation of PPAR-g causes a series of reactions that reg-
ulates the production of proinflammatory cytokines,
including interleukin (IL)-6.19 The variant allele of the
PPARG Pro12Ala polymorphism has been shown to be asso-
ciated with a reduced transcriptional activity of PPAR-g.20
As such, this polymorphism has been hypothesized to
contribute to an increased cancer risk. Our findings indicate
that the Pro/Ala genotype of the PPARG Pro12Ala poly-
morphism was associated with an increased ovarian cancer
risk. However, the association was absent for the variant
Ala/Ala genotype. Such an observation could be due to the
complex regulatory role of PPAR-g on cancer-related cy-
tokines production (such as IL-6) during carcinogenesis,
although this assumption requires further investigation.
Considering the complex relationship between PPAR-g and
IL-6, we also investigated the association between IL6
polymorphism with ovarian cancer risk. The IL6-174G/C
promoter polymorphism was selected as it harbors binding
sites for multiple transcription factors and the poly-
morphism has been known to regulate IL-6 protein expres-
sion in vivo and in vitro.21 We found that the IL6
polymorphism was associated with a reduced risk of cancer,
but without statistical significance although the p value was
low (p Z 0.08). For the PPARG Pro12Ala polymorphism,
contrary to our findings, several other authors did not find
an association between the polymorphism with the risk of
breast and lung cancers.9,22 For the IL6-174G/C promoter
polymorphism, our finding was in partial agreement with
Campa et al22 who showed no association between the
polymorphism and nonsmall cell lung cancer in general
(although the association became apparent when squamous
cell carcinomas of the lung were analyzed separately). To
our knowledge, this is the first report on the association of
the two polymorphisms and ovarian cancer risk.
We also investigated the association between E-selectin
S128R (A561C) polymorphism and ovarian cancer risk. We
showed that the variant allele of the polymorphism was
associated with an increased ovarian cancer risk. E-selectin
is a calcium-dependent cell adhesion molecule which istheir association with ovarian cancer risk.
Controls (n Z 687) OR (95% CI) p
172 Reference d
241 1.09 (0.83e1.44) 0.54
65 1.30 (0.88e1.92) 0.19
72 0.88 (0.58e1.31) 0.52
93 1.07 (0.75e1.53) 0.72
25 1.24 (0.70e2.21) 0.47
9 0.12 (0.01e0.95) 0.04
5 2.56 (0.88e7.44) 0.08
5 1.50 (0.47e4.81) 0.50
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mation. It has been shown that many metastasizing cells
exploit the expression of E-selectin to extravasate from the
microvasculature.23 The interaction between E-selectin
and its ligands could activate several signaling pathways,
such as the MAPK pathway, which confer selective survival
advantage for cancer cells.24 The variant allele of the E-
selectin S128R (A561C) polymorphism results in an
increased affinity of E-selectin for its ligands.25 Hence, the
variant allele could be associated with an increased cancer
risk, which explains our observations in the current study.
Similar to our study, Xia et al12 reported that the variant
allele of the polymorphism was associated with an
increased risk of gastric cancer in a Chinese population. In
addition, several previous studies also demonstrated that
the variant allele was associated with poor prognosis of
colorectal and breast cancers.26,27 This is the first report
investigating the association of E-selectin polymorphism
with the risk of ovarian cancer.
NFKB1 and NFKBIA encode for nuclear factor-kappa B
(NF-kB), and its inhibitor, IkBa, respectively. NF-kB has
been thought to be the master regulator in the inflam-
matory pathway. Therefore, the polymorphisms in NFKB1
and NFKBIA genes could present differential risk of various
cancers in different individuals. We investigated the as-
sociation of NFKB1-94 ins/del polymorphism and NFKBIA-
826C/T polymorphism with ovarian cancer risk. We found
that the ins/ins genotype of the NFKB1 polymorphism was
associated with an increased ovarian cancer risk. This is
explained by the fact that the ins allele causes a higher
transcriptional activity, which eventually produces a
higher level of its protein product that mediates the in-
flammatory pathway. Our findings agree with those of Fan
et al13 and Suzairi et al14 but disagree with those of
Andersen et al28 and Riemann et al29 probably due to the
different genetic backgrounds of the study participant
included. For the NFKBIA polymorphism, we found no as-
sociation of the polymorphism and ovarian cancer risk.
This is consistent with the findings of Tan et al15 but dis-
agrees with the findings of Lin et al.30 We also investigated
the association between combinations of various NFKB1
and NFKBIA genotypes with ovarian cancer risk. Interest-
ingly, we showed that out of all the possible combinations,
only the NFKB1 del/del þ NFKBIA TT combination was
associated with ovarian cancer risk. This highlights the
complex interaction between NFKB1 and NFKBIA in
modulating cancer risk.
Intercellular adhesion molecule-1 (ICAM-1) is a cell
adhesion molecule which also plays a pivotal role in in-
flammatory responses. Specifically, it facilitates the trans-
port of leukocytes to inflammatory sites, which further
contributes to the instability of the tumor environment. We
investigated the association between ICAM-1 K469E poly-
morphism and ovarian cancer risk, and showed the pres-
ence of an association between the heterozygous KE
genotype and a decreased ovarian cancer risk. This is
inconsistent with the findings of Tian et al10 who found that
the KK genotype was associated with an increased gastric
cancer risk, as well as the findings of Cai et al16 who showed
that the variant EE genotype was associated with an
increased the risk of ovarian cancer. In our study, the
variant EE genotype was not associated with ovarian cancerrisk. This suggests that the risk modification effect of the
variant allele was not dose dependent.Conclusion
We have successfully established the association of PPARG
Pro12Ala polymorphism, IL6-174G/C polymorphism, E-
selectin S128R (A561C) polymorphism, NFKB1-94 ins/del
polymorphism, NFKBIA-826C/T polymorphism, and ICAM-1
K469E polymorphism with ovarian cancer risk in a Chinese
population. Our results showed that the PPARG Pro/Ala
genotype, E-selectin AC genotype, and NFKB1 ins/ins ge-
notype were associated with an increased ovarian cancer
risk in the population studied. In addition, the ICAM-1 KE
genotype was associated with a reduced ovarian cancer
risk. However, no association was found between the IL6
and NFKBIA polymorphisms and ovarian cancer risk. Infor-
mation regarding genetic associations is only valuable when
functional assays are performed to investigate the role of
the genetic variation in carcinogenesis, or when the asso-
ciations are replicated in independent cohorts. The former
approach is time-consuming, and requires manpower and
budget, therefore, the present study focused on the repli-
cation of the associations in independent cohorts. Out of
the four polymorphisms found to be associated with ovarian
cancer risk in our study, only two (i.e., NFKB1 -94 ins/del
and ICAM-1 K469E) had been previously demonstrated in
ovarian cancer.13,16 These two polymorphisms could serve
as genetic biomarkers for ovarian cancer, while the utility
of the other four polymorphisms as genetic biomarkers are
waiting for further confirmation in independent cohorts of
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